| Biomarker ID | 524 |
| PMID | 20473869 |
| Year | 2010 |
| Biomarker | miRNA-375, miRNA-141 and miRNA-200b |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miRNA-375):- DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome Pathways Include(miRNA-141):- regulation of RNA metabolic process; Gene expression (Transcription); RNA Polymerase II Transcription; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific Pathways Incude(miRNA-200b):- MicroRNAs in cancer; Gene expression (Transcription); RNA Polymerase II Transcription ; nucleoplasm; DNA binding |
| Experiment | Pathoglical Stage pt3 vs pt2 |
| Type of Biomarker | Prognostic |
| Cohort | 45 serum samples from 42 patients were taken for first validation study out of which 3 were metastatic. pt3 (n=23) and pt2 (n=19) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | miRNA-375, miRNA-141, miRNA-200b |